Researchers determined the presence of pulmonary hypertension was associated with worse outcomes for patients with polycythemia vera.

We are thrilled to welcome Jay to the Agios Board of Directors,” said Brian Goff, Chief Executive Officer, Agios. “His deep scientific insight, extensive regulatory expertise, and strategic business ...

Panelists discuss how the future treatment landscape for myeloproliferative neoplasms is evolving with many promising ...

Panelists discuss how rusfertide, a hepcidin mimetic peptide, shows promise in polycythemia vera by reducing phlebotomy ...

The finding that basophil counts may have prognostic significance aligns with a growing body of research into basophils in ...

Incyte INCY has put up a good performance in the past three months. Shares of the company have gained 9.2% against the ...

A novel oral peptide PN-477o with once-daily dosing, high potency and activation of glucagon-like peptide-1 (GLP-1), ...

Discover the critical importance of vitamin B12 in combating fatigue and maintaining overall health. Cardiologist Dr. Alok Chopra explores dietary sources, deficiency signs, and the risks for ...

June brought major blood cancer updates, and CURE is sharing the latest in myelofibrosis treatment and FDA breakthroughs, as well as survivorship news.

Merck's growing pipeline, with nearly 20 new launches ahead, is set to reshape its portfolio as Keytruda's 2028 patent expiry nears.

Webcast and conference call to be held on Monday, June 30th at 4:30 pm ET, dial in information below NEWARK, CA / ACCESS Newswire / June 26, 2025 / Protagonist Therapeutics, Inc. (“Protagonist” or the ...